Skip to content

Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)

Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07212751
Acronym
CT-PLAQUE
Enrollment
22000
Registered
2025-10-08
Start date
2020-01-29
Completion date
2027-12-31
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All-cause Death, Calcified Plaque, Cardiovascular Death, CT Plaque, FFR-CT, Non-calcified Plaque, Nonfatal Myocardial Infarction, Nonfatal Stroke, Stroke (Subacute)

Keywords

CTCA, CT, Coronary CT, Calcium Score, Plaque, Coronary Artery Disease, CAD, Chest pain

Brief summary

The study aims at determining if the presence of adverse plaque features identified from the CT angiogram can help determine prognosis and guide treatment options.

Interventions

DIAGNOSTIC_TESTCTCA

Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment \- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

Sponsors

The University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years

Inclusion criteria

* Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment * If multiple CTAs are taken, the most updated one before treatment commencement will be chosen.

Exclusion criteria

* Patient who did not undergo cardiac CT scan due to inability to undergo cardiac CT scanning, kidney failure (serum creatinine \>250 μmol/L or estimated glomerular filtration rate \<30 mL/min), major allergy to contrast.

Design outcomes

Primary

MeasureTime frame
Nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death and all-cause death5 years after CTCA examinations

Secondary

MeasureTime frame
Total plaque (mm³) to predict cardiac events5 years after CTCA examinations
Calcified plaque (mm³) to predict cardiac events5 years after CTCA examinations
Non-calcified plaque (mm³) to predict cardiac events5 years after CTCA examinations
CT-FFR to predict cardiac events5 years after CTCA examinations

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026